tiprankstipranks
Advertisement
Advertisement
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
PremiumThe FlyBioCryst price target raised to $29 from $27 at Cantor Fitzgerald
1M ago
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target
Premium
Ratings
Analyst Reaffirms Buy on BioCryst as Company Streamlines R&D, Maintains 2026 Outlook and Sets $16 Price Target
1M ago
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
Premium
Company Announcements
BioCryst Advances Rare Disease Pipeline Amid Cost Controls
1M ago
BioCryst Earnings Call: ORLADEYO Momentum vs. Risks
PremiumCompany AnnouncementsBioCryst Earnings Call: ORLADEYO Momentum vs. Risks
2M ago
BioCryst price target raised to $28 from $25 at Citizens
Premium
The Fly
BioCryst price target raised to $28 from $25 at Citizens
3M ago
BioCryst reports Q1 EPS ($2.98), consensus 11c
Premium
The Fly
BioCryst reports Q1 EPS ($2.98), consensus 11c
3M ago
BioCryst Licenses European Rights to HAE Drug Navenibart
PremiumCompany AnnouncementsBioCryst Licenses European Rights to HAE Drug Navenibart
3M ago
BioCryst enters navenibart license agreement with Neopharmed Gentili
Premium
The Fly
BioCryst enters navenibart license agreement with Neopharmed Gentili
3M ago
BioCryst Pharmaceuticals (BCRX) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
BioCryst Pharmaceuticals (BCRX) Q1 Earnings Cheat Sheet
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100